The move came after an independent panel of experts appointed to supervise the trial expressed concern that AstraZeneca had failed to include updated data in its initially released figure.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3coEbqx
via IFTTT
0 comments:
Post a Comment